Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Addiphos concentrate for solution for infusion
Medicines register · Ireland

Addiphos concentrate for solution for infusion

Authorisation PA2059/024/001 · Fresenius Kabi Deutschland GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Fresenius Kabi Deutschland GmbH (all products →)
Active substances
Potassium dihydrogen phosphate, Potassium hydroxide, Disodium phosphate dihydrate
Dosage form
Concentrate for solution for infusion
Route of administration
Intravenous use
ATC codes
B05XA, B05XA30
First authorised
01/04/1983
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Potassium dihydrogen phosphate: supply and approvals

2 authorised products on the HPRA list contain Potassium dihydrogen phosphate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Potassium hydroxide: supply and approvals

1 authorised product on the HPRA list contains Potassium hydroxide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Disodium phosphate dihydrate: supply and approvals

4 authorised products on the HPRA list contain Disodium phosphate dihydrate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 43 years (since 1 April 1983). The HPRA list marks it as marketed in Ireland.

Other medicines with Potassium dihydrogen phosphate in Ireland

4 other products on the HPRA list contain Potassium dihydrogen phosphate, from 1 licence holder; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Potassium Phosphate 1mmol/ml + 0.6mmol/ml Concentrate for Solution for InfusionB. Braun Melsungen AGNational authorisation (PA)Marketed
Nutriflex basal solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed
Nutriflex peri solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed
Nutriflex special solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed

Other medicines with Potassium hydroxide in Ireland

4 other products on the HPRA list contain Potassium hydroxide, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Nutriflex basal solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed
Nutriflex peri solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed
Nutriflex plus solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed
Nutriflex special solution for infusionB. Braun Melsungen AGNational authorisation (PA)Not marketed

Other substances in ATC group B05XA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 23 other active substances share the group B05XA with this product:

Sodium chloride (6) · Potassium chloride (4) · Potassium iodide (3) · Sodium fluoride (2) · Sodium selenite anhydrous (2) · Zinc chloride (2) · Sodium bicarbonate (1) · Chromic chloride hexahydrate (1) · Copper chloride dihydrate (1) · Ferric chloride hexahydrate (1) · Manganese chloride tetrahydrate (1) · Sodium molybdate dihydrate (1) · Calcium chloride dihydrate (1) · Zinc gluconate (1) · Copper gluconate (1) · Manganese Gluconate (1) · Sodium selenite (1) · Magnesium sulphate heptahydrate (1) · Copper chloride 2H2O (1) · Manganese chloride 4H2O (1) · and 3 more

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Fresenius Kabi Deutschland GmbH holds 164 products on the HPRA list, with 164 different active substances; 69 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.